文献速递血液净化与透析

维持性血液透析试验中血管通路结局报告的系统综述

Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review.
PubMed 文献 · Am J Kidney Dis · 2017-12-06

该系统综述纳入168项随机对照试验及试验方案,提取1426项血管通路相关结局指标,归为23类。最常见的结局为功能(81%)、感染(38%)和成熟(18%),但测量方式高度异质,患者报告结局极少,标准化定义使用不足。

要点

  • 血管通路结局报告高度异质,功能指标有489种测量方式。
  • 患者报告结局如疼痛(11%)和生活质量(3%)报告率低。
  • 仅少数试验采用既往标准化结局定义,需推动标准化。

核心结论

  • 血液透析试验中血管通路结局报告非常异质,患者报告结局有限,标准化结局措施使用不频繁。

研究设计与样本

  • 系统综述,纳入2011年1月至2016年6月来自ClinicalTrials.gov、Embase、MEDLINE和Cochrane肾脏与移植专业注册库的168项相关随机对照试验及试验方案。

主要发现

  • 从168项试验中提取1426项通路相关结局指标,归为23种不同结局。
  • 最常见的3种结局为功能(136项[81%]试验)、感染(63项[38%])和成熟(31项[18%])。
  • 功能有489种不同测量方式,最常报告为平均通路血流量(mL/min)(37项[27%])和血栓形成数量(30项[22%])。
  • 感染有136种评估方式,最常用为通路相关感染数量。
  • 成熟有44种评估方式、15个不同时间点,最常以静脉直径和血流量描述。

临床怎么用

  • 临床解读血液透析血管通路试验时需注意结局指标的高度异质性。
  • 应关注功能、感染和成熟等核心结局的标准化定义。

局限性

  • 采样框架受限,仅关注当代试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many randomized controlled trials have been performed with the goal of improving outcomes related to hemodialysis vascular access. If the reported outcomes are relevant and measured consistently to allow comparison of interventions across trials, such trials can inform decision making. This study aimed to assess the scope and consistency of vascular access outcomes reported in contemporary hemodialysis trials. STUDY DESIGN: Systematic review. SETTING & POPULATION: Adults requiring maintenance hemodialysis. SELECTION CRITERIA: All randomized controlled trials and trial protocols reporting vascular access outcomes identified from ClinicalTrials.gov, Embase, MEDLINE, and the Cochrane Kidney and Transplant Specialized Register from January 2011 to June 2016. INTERVENTIONS: Any hemodialysis-related intervention. OUTCOMES: The frequency and characteristics of vascular access outcome measures were analyzed and classified. RESULTS: From 168 relevant trials, 1,426 access-related outcome measures were extracted and classified into 23 different outcomes. The 3 most common outcomes were function (136 [81%] trials), infection (63 [38%]), and maturation (31 [18%]). Function was measured in 489 different ways, but most frequently reported as "mean access blood flow (mL/min)" (37 [27%] trials) and "number of thromboses" (30 [22%]). Infection was assessed in 136 different ways, with "number of access-related infections" being the most common measure. Maturation was assessed in 44 different ways at 15 different time points and most commonly characterized by vein diameter and blood flow. Patient-reported outcomes, including pain (19 [11%]) and quality of life (5 [3%]), were reported infrequently. Only a minority of trials used previously standardized outcome definitions. LIMITATIONS: Restricted sampling frame for feasibility and focus on contemporary trials. CONCLUSIONS: The reporting of access outcomes in hemodialysis trials is very heterogeneous, with limited patient-reported outcomes and infrequent use of standardized outcome measures. Efforts to standardize outcome reporting for vascular access are critical to optimizing the comparability, reliability, and value of trial evidence to improve outcomes for patients requiring hemodialysis.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Viecelli AK, O'Lone E, Sautenet B, et al. Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. Am J Kidney Dis. 2017. PMID: 29203125. doi:10.1053/j.ajkd.2017.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。